<DOC>
	<DOC>NCT00679484</DOC>
	<brief_summary>This study will compare olmesartan medoxomil to candesartan cilexetil in reducing BNP, a prognostic biomarker of heart failure, at week 24</brief_summary>
	<brief_title>Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<criteria>Male or female, adult, outpatients aged between 18 and 85 years Patients with documented hospital admission within the previous 3 months before randomization with discharge diagnosis of CHF Patients with functional NYHA class IIIV with LVEF &lt; 40% assessed within the last 3 months Patients with blood BNP levels &gt; 400 pg/ml or NTProBNP levels &gt; 1500 pg/ml Patients with CHF due to ischemic heart disease, idiopathic dilated cardiomyopathy (IDC), mitral or aortic insufficiency or hypertension Patients with stable conventional treatment with diuretics, ACEI and/or betablockers and/or aldosterone antagonists for at least 2 months prior to randomisation, unless documented contraindication or intolerance Females who are pregnant or plan a pregnancy during the time of the trial, are nursing or are of childbearing potential and not using acceptable methods of contraception. If a female becomes pregnant during the study, she has to be withdrawn immediately Patients with current hospitalisation due to heart failure Patients with stroke or transient ischemic attack (TIA) within the last 3 months Patients with acute coronary syndrome, myocardial infarction, coronary artery bypass or angioplasty within 3 months Planned cardiac surgery, revascularization or resynchronization within the study period Patients with operable valvular disease or significant obstructive cardiomyopathy Patients with bradycardia [heart rate (HR) &lt; 50 bpm] Patients with hypotension [systolic blood pressure (SBP) &lt; 90 mmHg] Patients with obstructive pneumopathy Patients with clinical significant renal failure (creatininemia &gt; 200 micromol/l)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>